
Savran Technologies
Savran Technologies: Revolutionizing non-invasive diagnostics for cancer and prenatal care.

Savran Technologies: Revolutionizing non-invasive diagnostics for cancer and prenatal care.
Savran Technologies, founded in the Boston area, is a biotech company dedicated to revolutionizing non-invasive diagnostics. Their core mission is to enhance the monitoring of cancer patients and provide comprehensive genetic insights during early pregnancy. Utilizing unique, patented micro-fluidic designs and processes, Savran Technologies offers advanced systems for the capture and detection of ultra-rare cells from blood. Their streamlined workflow, which can operate with or without a centrifuge, positions them at the forefront of rare cell detection platforms.
Notable figures affiliated with Savran Technologies include experts in biotechnology and diagnostics, although specific names are not provided. The company has garnered attention for its innovative approach and has likely attracted significant investment from venture capitalists interested in cutting-edge medical diagnostics. Savran Technologies' key achievements include the development of their patented micro-fluidic technology, which has the potential to significantly impact cancer treatment and prenatal care by providing early and accurate diagnostic information.
Companies similar to Savran Technologies include Ravgen, BioFluidica, Cellscape and EarlyCell.
Savran Technologies was founded in 2018.
Savran Technologies' headquarters is located in Newton, MA, US.
Savran Technologies' most recent funding round was for $304.4k (USD) in March 2023.
As of Mar 7, 2023, Savran Technologies has disclosed funding of $5.8M (USD). Undisclosed round amounts are excluded.
Savran Technologies has 9 employees as of Feb 5, 2024.
EarlyCell